Chlorthalidone

Chlorthalidone is a thiazide-like diuretic taken by mouth. The US label read, for Thalitone, lists two uses: the treatment of hypertension, to lower blood pressure, and, in adults, adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome. Thalitone is one brand; other chlorthalidone tablets have their own labels, which were not read.

Also called Thalitone · Chlortalidone

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 2409; UNII Q0MQD1073Q. MeSH descriptor D002752 is Chlorthalidone. Class: Thiazide-like Diuretic (FDA established pharmacologic class, RxClass). The label read is the THALITONE (chlorthalidone) tablets, Casper Pharma LLC label, effective 2026-06-25 in openFDA (application NDA019574). Other chlorthalidone labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 5 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
5
Phase 3 or 4
4
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedTerminatedUnknown statusAll statuses
Phase 21001
Phase 42114
All phases3115

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
Not reported

Claims and evidence

Context People for whom the US label of chlorthalidone (Thalitone) lists an indication: hypertension, edema (including edema of heart failure)

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. Only the edema sentence says adults; the hypertension passage read does not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Only the edema sentence says adults; the hypertension passage read does not state an age range
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Patients with hypertension
  • Adults with edema associated with heart failure, cirrhosis of the liver, or renal disease including nephrotic syndrome
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of THALITONE (chlorthalidone), in the Casper Pharma LLC version dated 2026-06-25 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, and, in adults, as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome.

    Applies to Recipient not specified People for whom the US label of chlorthalidone (Thalitone) lists an indication: hypertension, edema (including edema of heart failure)

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for THALITONE (chlorthalidone) tablets, Casper Pharma LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id bc5a0299-115b-4e60-bb3f-c75a95c51c15 (manufacturer Casper Pharma LLC, application NDA019574), returned on 2026-11-09. The label text is dated 2026-06-25 (effective_time). Other openFDA records of chlorthalidone labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0]
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2026-06-25
      Source state
      Current
      Version fingerprint
      b8ddb25b1964616c0cf70118ed5dcb0d5be237fbde35a857491f11293305ae5a
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for THALITONE (chlorthalidone) tablets, Casper Pharma LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id bc5a0299-115b-4e60-bb3f-c75a95c51c15 (manufacturer Casper Pharma LLC, application NDA019574), returned on 2026-11-09. The label text is dated 2026-06-25 (effective_time). Other openFDA records of chlorthalidone labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260625.
      Retrieved
      Source effective date
      2026-06-25
      Source state
      Current
      Version fingerprint
      b8ddb25b1964616c0cf70118ed5dcb0d5be237fbde35a857491f11293305ae5a
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

COMBIPRES

No label from the application holder was found in the openFDA label dataset for application NDA017503. This page does not show another labeler's label in its place.

EDARBYCLOR

No label from the application holder was found in the openFDA label dataset for application NDA202331. This page does not show another labeler's label in its place.

HEMICLOR

No label from the application holder was found in the openFDA label dataset for application NDA218647. This page does not show another labeler's label in its place.

HYGROTON

No label from the application holder was found in the openFDA label dataset for application NDA012283. This page does not show another labeler's label in its place.

KERLEDEX

No label from the application holder was found in the openFDA label dataset for application NDA019807. This page does not show another labeler's label in its place.

REGROTON

No label from the application holder was found in the openFDA label dataset for application NDA015103. This page does not show another labeler's label in its place.

TENORETIC 100

No label from the application holder was found in the openFDA label dataset for application NDA018760. This page does not show another labeler's label in its place.

THALITONE

No label from the application holder was found in the openFDA label dataset for application NDA019574. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA012283 HYGROTON
  2. Approval NDA015103 REGROTON
  3. Approval NDA017503 COMBIPRES
  4. Approval NDA018760 TENORETIC 100
  5. Approval NDA019574 THALITONE
  6. Approval NDA019807 KERLEDEX
  7. Approval NDA202331 EDARBYCLOR
  8. Approval NDA218647 HEMICLOR

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 8

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA012283

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...

    ProductNDA015103

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA017503

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...

    ProductNDA018760

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019574

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019807

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA202331

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA218647

Registry trials 5

Record details

Record id
cardio:chlorthalidone
Content hash
62ed722b4a7532805391080ba3b7e088911c4c70dc75b684940b0c30f22e8ed6